<DOC>
	<DOCNO>NCT01433614</DOCNO>
	<brief_summary>Anthracycline-taxane regimen effective mean postpone progression metastatic breast cancer . It yet unclear whether addition capecitabine combination improve treatment outcome . Patients advance breast cancer randomize first-line chemotherapy combination epirubicin ( Farmorubicin® ) paclitaxel ( Taxol® ) alone ( ET ) combination capecitabine ( Xeloda® , TEX ) . Starting dos ET epirubicin 75 mg/m2 plus paclitaxel 175 mg/m2 , TEX epirubicin 75mg/m2 , paclitaxel 155 mg/m2 , capecitabine 825 mg/m2 BID 14 day . Subsequently , dos tailor related side effect . Primary endpoint progression-free survival ( PFS ) ; secondary endpoint overall survival ( OS ) , time treatment failure ( TTF ) , objective response ( OR ) , safety quality life ( QoL ) .</brief_summary>
	<brief_title>Epirubicin Paclitaxel , Alone Together With Capecitabine First Line Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Morphologically prove breast carcinoma Written patient consent must obtain Measurable disease ( i.e . least one lesion accurately measure least one dimension ≥20 mm conventional technique , ≥10 mm spiral CT scan ) define section 8 . Lytic blastic bone metastases site recurrence allow Age 18 year old ECOG performance status 02 Life expectancy least three month Adequate cardiac function Adequate hematological , renal hepatic function Patient must accessible treatment followup . Treatmentfree interval less one year , previous adjuvant , neoadjuvant radically treat locoregional recurrence give regimen contain anthracycline , taxane capecitabine . This limitation apply regimen contain drug mention During adjuvant treatment obtain cumulative dos exceed 375 mg/m2 doxorubicin , 550 mg/m2 epirubicin , abnormal ECG reduce cardiac function measure leave ventricular ejection fraction ( LVEF ) . Indication use trastuzumab ( Herceptin ) firstline treatment patient tumor overexpressing cerbB2 . Any previous chemotherapy metastatic disease , except radically treat locoregional relapse Neoplasm breast carcinoma , except nonmelanoma skin cancer curatively treat carcinoma situ cervix , diagnose past five year Pregnancy lactation Known brain metastasis History atrial ventricular arrhythmia and/or congestive heart failure , even medically control . History clinical electrocardiographically document myocardial infarction Preexisting motor sensory neuropathy ≥ grade 2 accord NCI CTC 2.0 criterion ( severe paresthesia and/or mild weakness , bad ) Severe hepatic renal impairment ( capecitabine : calculated creatinine clearance 30 ml/min ; calculation , see p. 5.1.4 ) allow adequate use propose regimen History know dihydropyrimidine dehydrogenase ( DPD ) deficiency ( severe reaction previous treatment fluorouracil , e.g experience mucositis , handfoot syndrome , diarrhea ) Active infection serious underlie medical condition would impair ability patient receive protocol treatment , include prior allergic reaction drug contain cremophor , teniposide , cyclosporin vitamin K Dementia significantly alter mental status would prohibit understanding give informed consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>